JP2019535670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535670A5 JP2019535670A5 JP2019521046A JP2019521046A JP2019535670A5 JP 2019535670 A5 JP2019535670 A5 JP 2019535670A5 JP 2019521046 A JP2019521046 A JP 2019521046A JP 2019521046 A JP2019521046 A JP 2019521046A JP 2019535670 A5 JP2019535670 A5 JP 2019535670A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 239000011230 binding agent Substances 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 10
- 208000005017 glioblastoma Diseases 0.000 claims 8
- 208000000172 Medulloblastoma Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000044752 human PROM1 Human genes 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410162P | 2016-10-19 | 2016-10-19 | |
| US62/410,162 | 2016-10-19 | ||
| US201762472209P | 2017-03-16 | 2017-03-16 | |
| US62/472,209 | 2017-03-16 | ||
| PCT/CA2017/051245 WO2018072025A1 (en) | 2016-10-19 | 2017-10-19 | Cd133-binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535670A JP2019535670A (ja) | 2019-12-12 |
| JP2019535670A5 true JP2019535670A5 (enExample) | 2020-11-26 |
| JP7231158B2 JP7231158B2 (ja) | 2023-03-01 |
Family
ID=62018307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521046A Active JP7231158B2 (ja) | 2016-10-19 | 2017-10-19 | Ｃｄ１３３結合剤およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11220551B2 (enExample) |
| EP (1) | EP3529279A4 (enExample) |
| JP (1) | JP7231158B2 (enExample) |
| CN (1) | CN110352198B (enExample) |
| WO (1) | WO2018072025A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20191703A1 (es) * | 2017-03-27 | 2019-11-27 | Hoffmann La Roche | Formatos mejorados de receptor de union a antigeno |
| CN110526987A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 靶向cd133的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109735500B (zh) * | 2019-01-25 | 2023-05-16 | 苏州茂行生物科技有限公司 | 一种分泌型靶向cd133的car-t细胞及其制备方法和应用 |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| GB2599546A (en) * | 2019-05-31 | 2022-04-06 | Univ Johns Hopkins | IL-ER#/IL-8R Bispecific binding agents for inhibiting cancer cell migration |
| CN113912695B (zh) * | 2019-07-24 | 2023-05-30 | 暨南大学 | 靶向cd133的结合蛋白及应用 |
| JP2023530109A (ja) | 2020-06-11 | 2023-07-13 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| CN111529690B (zh) * | 2020-06-17 | 2023-03-31 | 中国科学院昆明动物研究所 | 人cd133蛋白1-108肽段的新用途 |
| CN114057875B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| JP2023543017A (ja) * | 2020-09-27 | 2023-10-12 | ジェネンテック， インコーポレイテッド | ハイスループットマルチパラメータ免疫細胞エンゲージャースクリーニングアッセイ |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| JP2024505075A (ja) | 2021-01-29 | 2024-02-02 | アロジーン セラピューティクス，インコーポレイテッド | 同種細胞産物のＴ細胞認識を軽減するための、ＴＡＰ２、ＮＬＲＣ５、β２ｍ、ＴＲＡＣ、ＲＦＸ５、ＲＦＸＡＰ及びＲＦＸＡＮＫのうち１つ以上のノックダウン又はノックアウト |
| US20250129160A1 (en) * | 2021-06-04 | 2025-04-24 | Amgen Research (Munich) Gmbh | T cell engager molecules and uses thereof |
| CN114213537B (zh) * | 2021-12-24 | 2022-06-14 | 北京市神经外科研究所 | Cd133抗体、嵌合抗原受体及其应用 |
| CN114316050B (zh) * | 2021-12-24 | 2022-11-11 | 北京市神经外科研究所 | Cd133抗体、嵌合抗原受体及其应用 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| AU2023312973A1 (en) | 2022-07-29 | 2025-01-09 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025056957A1 (en) * | 2023-09-15 | 2025-03-20 | Jimenez Mendoza, Dimas | Peptide based medicines for treating cancer |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN118108849B (zh) * | 2024-04-28 | 2024-06-25 | 苏州睿瀛生物技术有限公司 | 一种抗cd33的纳米抗体制备方法和抗体的荧光标记流式应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2065397A1 (en) * | 2007-11-20 | 2009-06-03 | Miltenyi Biotech GmbH. | Method for the separation of cells |
| EP2769989A1 (en) * | 2013-02-21 | 2014-08-27 | Universitätsklinikum Freiburg | Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor |
| US10711068B2 (en) | 2015-03-26 | 2020-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD133 monoclonal antibodies and related compositions and methods |
| CA2962157A1 (en) * | 2016-10-19 | 2018-04-19 | The Governing Council Of The University Of Toronto | Cd133-binding agents and uses thereof |
-
2017
- 2017-10-19 WO PCT/CA2017/051245 patent/WO2018072025A1/en not_active Ceased
- 2017-10-19 CN CN201780078237.3A patent/CN110352198B/zh active Active
- 2017-10-19 JP JP2019521046A patent/JP7231158B2/ja active Active
- 2017-10-19 US US16/342,807 patent/US11220551B2/en active Active
- 2017-10-19 EP EP17863201.4A patent/EP3529279A4/en active Pending
-
2021
- 2021-10-26 US US17/511,420 patent/US20220073640A1/en active Pending